The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy
Open accessAbstract
BACKGROUND: Transmitted HIV-1 drug resistance can compromise initial antiretroviral therapy (ART); therefore, its detection is important for patient management. The absence of drug-associated selection pressure in treatment-naïve persons can cause drug-resistant viruses to decline to levels undetectable by conventional bulk sequencing (minority drug-resistant variants). We used sensitive and simple tests to investigate evidence of transmitted drug resistance in antiretroviral drug-naïve persons and assess the clinical implications of minority drug-resistant variants. METHODS AND FINDINGS: We performed a cross-sectional analysis of transmitted HIV-1 drug resistance and a case-control study of the impact of minority drug resistance on treatment response. For the cross-sectional analysis, we examined viral RNA from newly diagnosed ART-naïve persons in the US and Canada who had no detectable (wild type, n = 205) or one or more resistance-related mutations (n = 303) by conventional sequencing. Eight validated real-time PCR-based assays were used to test for minority drug resistance mutations (protease L90M and reverse transcriptase M41L, K70R, K103N, Y181C, M184V, and T215F/Y) above naturally occurring frequencies. The sensitive real-time PCR testing identified one to three minority drug resistance mutation(s) in 34/205 (17%) newly diagnosed persons who had wild-type virus by conventional genotyping; four (2%) individuals had mutations associated with resistance to two drug classes. Among 30/303 (10%) samples with bulk genotype resistance mutations we found at least one minority variant with a different drug resistance mutation. For the case-control study, we assessed the impact of three treatment-relevant drug resistance mutations at baseline from a separate group of 316 previously ART-naïve persons with no evidence of drug resistance on bulk genotype testing who were placed on efavirenz-based regimens. We found that 7/95 (7%) persons who experienced virologic failure had minority drug resistance mutations at baseline; however, minority resistance was found in only 2/221 (0.9%) treatment successes (Fisher exact test, p = 0.0038). CONCLUSIONS: These data suggest that a considerable proportion of transmitted HIV-1 drug resistance is undetected by conventional genotyping and that minority mutations can have clinical consequences. With no treatment history to help guide therapies for drug-naïve persons, the findings suggest an important role for sensitive baseline drug resistance testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiretroviral-Drug Resistance among Patients Recently Infected with HIV
Little, S. J., Holte, S., Routy, J.-P., Daar, E. S., Markowitz, M., Collier, A. C., Koup, R. A., Mellors, J. W., Connick, E., Conway, B., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013552 · Cited by 1,140
Time Trends in Primary HIV-1 Drug Resistance Among Recently Infected Persons
Grant, R. M. (2002) · JAMA · doi:10.1001/jama.288.2.181 · Cited by 459
Simen, B. B., Simons, J. F., Hullsiek, K. H., Novak, R. M., MacArthur, R. D., Baxter, J. D., Huang, C., Lubeski, C., Turenchalk, G. S., Braverman, M. S., et al. (2009) · Journal of Infectious Diseases · doi:10.1086/596736 · Cited by 392
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
Shafer, R. W., Rhee, S.-Y., Pillay, D., Miller, V., Sandstrom, P., Schapiro, J. M., Kuritzkes, D. R., & Bennett, D. (2007) · AIDS · doi:10.1097/qad.0b013e328011e691 · Cited by 324
Self-citationWeinstock, H. S., Zaidi, I., Heneine, W., Bennett, D., Garcia‐Lerma, J. G., Douglas, Jr., LaLota, M., Dickinson, G., Schwarcz, S., Torian, L., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/420789 · Cited by 246
Self-citationDeJesus, E., Herrera, G., Teofilo, E., Gerstoft, J., Buendia, C. B., Brand, J. D., Brothers, C. H., Hernandez, J., Castillo, S. A., Bonny, T., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/424009 · Cited by 226
Self-citationGünthard, H. F., Wong, J. K., Ignacio, C. C., Havlir, D. V., & Richman, D. D. (1998) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1998.14.869 · Cited by 150
Garcia-Lerma, J. G., Nidtha, S., Blumoff, K., Weinstock, H., & Heneine, W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241300698 · Cited by 131
Self-citationCong, M., Heneine, W., & Garcia-Lerma, J. G. (2006) · Journal of Virology · doi:10.1128/jvi.02712-06 · Cited by 127
Self-citationMarcelin, A., Delaugerre, C., Wirden, M., Viegas, P., Simon, A., Katlama, C., & Cálvez, V. (2003) · Journal of Medical Virology · doi:10.1002/jmv.10550 · Cited by 123
Cited by
Domingo, E., Sheldon, J., & Perales, C. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05023-11 · Cited by 1,009
Antiretroviral therapy and management of HIV infection
Volberding, P. A., & Deeks, S. G. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60676-9 · Cited by 449
Simen, B. B., Simons, J. F., Hullsiek, K. H., Novak, R. M., MacArthur, R. D., Baxter, J. D., Huang, C., Lubeski, C., Turenchalk, G. S., Braverman, M. S., et al. (2009) · Journal of Infectious Diseases · doi:10.1086/596736 · Cited by 392
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine
Cihlar, T., & Ray, A. S. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.09.014 · Cited by 375
Li, J. Z. (2011) · JAMA · doi:10.1001/jama.2011.375 · Cited by 367
Self-citation
Metadata
- Authors
- Johnson, J. A., Li, J.-F., Wei, X., Lipscomb, J., Irlbeck, D., Craig, C., Smith, A., Bennett, D. E., Monsour, M., Sandstrom, P., Lanier, E. R., & Heneine, W.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-07-29
- Volume
- 5
- Issue
- 7
- Pages
- e158
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2032847961
- Cited by
- 371
- References
- 12
- FWCI
- 29.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy. https://app.cochat.ai/papers/10.1371/journal.pmed.0050158
- The paper
- Johnson, J. A., Li, J.-F., Wei, X., Lipscomb, J., Irlbeck, D., Craig, C., Smith, A., Bennett, D. E., Monsour, M., Sandstrom, P., Lanier, E. R., & Heneine, W. (2008). Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy. PLoS Medicine. https://doi.org/10.1371/journal.pmed.0050158
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.